Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Completed · Phase 2 · Has a placebo group

Conditions studied: Compensated Cirrhosis, Nonalcoholic Steatohepatitis

In brief

A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.

Key facts

Study ID
NCT04210245
Run by
NGM Biopharmaceuticals, Inc
People needed
160
Starts
2020-03-23
Expected to finish
2023-02-23
Last updated by the study team
2025-03-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.